Alt_names,Application_Notes,Clonality,Description,Dilutions,Host,Immunogen,Item_no,Name,Papers,Quantity,Source,Specificity,Url
"CEDLAP,DPD1,latency-associated peptide,TGFB,TGFB1,TGF-beta 1 protein,TGFbeta 1,TGF-beta 1,TGFbeta,TGF-beta-1,transforming growth factor beta-1,transforming growth factor, beta 1",,,,,,,7754-BH-005,Recombinant Human TGF-beta 1 (Human Cell-expressed) Protein,"Derynck, R. and K. Miyazono (2008) Cold Spring Harbor Laboratory Press p. 29. ,Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. ,:6982.,Wahl, S.M. (2006) Immunol. Rev. ,:213. ,Chang, H. , (2002) Endocr. Rev. ,:787. ,Lin, J.S. , (2006) Reproduction ,:179. ,Hinck, A.P. , (1996) Biochemistry ,:8517. ,Mittl, P.R.E. , (1996) Protein Sci. ,:1261. ,Derynck, R. ,. (1985) Nature ,:701. ,Miyazono, K. , (1988) J. Biol. Chem. ,:6407. ,Oklu, R. and R. Hesketh (2000) Biochem. J. ,:601. ,de Caestecker, M. , (2004) Cytokine Growth Factor Rev. ,:1. ,Zuniga, J.E. , (2005) J. Mol. Biol. ,:1052.",,<0.01 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-tgf-beta-1-human-cell-expressed-protein_7754-bh
"CEDLAP,DPD1,latency-associated peptide,TGFB,TGFB1,TGF-beta 1 protein,TGFbeta 1,TGF-beta 1,TGFbeta,TGF-beta-1,transforming growth factor beta-1,transforming growth factor, beta 1",,,,,,,240-B-002,Recombinant Human TGF-beta 1 Protein,"Derynck, R. and K. Miyazono (2008) Cold Spring Harbor Laboratory Press, 29. ,Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. ,:6982. ,Wahl, S.M. (2006) Immunol. Rev. ,:213. ,Chang, H. , (2002) Endocr. Rev. ,:787. ,Lin, J.S. , (2006) Reproduction ,:179. ,Hinck, A.P. , (1996) Biochemistry ,:8517. ,Mittl, P.R.E. , (1996) Protein Sci. ,:1261. ,Derynck, R. ,. (1985) Nature ,:701. ,Miyazono, K. , (1988) J. Biol. Chem. ,:6407. ,Oklu, R. and R. Hesketh (2000) Biochem. J. ,:601. ,de Caestecker, M. , (2004) Cytokine Growth Factor Rev. ,:1. ,Zuniga, J.E. , (2005) J. Mol. Biol. ,:1052.",,TGFB1,,https://www.novusbio.com/products/recombinant-human-tgf-beta-1-protein_240-b
"B cell stimulatory factor-2,B-cell differentiation factor,BSF-2,BSF2CTL differentiation factor,CDF,HGFHSFIFNB2Hybridoma growth factor,IFN-beta-2,IL6,IL-6,IL-6B-cell stimulatory factor 2,Interferon beta-2,interleukin 6 (interferon, beta 2),interleukin BSF-2,interleukin-6,MGI-2A",,,,,,,7270-IL-025,Recombinant Human IL-6 (HEK293-expressed) Protein,"Mansell, A. and B.J. Jenkins (2013) Cytokine Growth Factor Rev. ,:249.,Schuett, H. , (2009) Thromb. Haemost. ,:215.,Erta, M. ,. (2012) Int. J. Biol. Sci. ,:1254.,Garbers, C. ,. (2012) Cytokine Growth Factor Rev. ,:85.,Mihara, M. ,. (2012) Clin. Sci. (Lond.) ,:143.,Hirano, T. ,. (1986) Nature ,:73.,Kestler, D.P. ,. (1995) Blood ,:4559.,Kestler, D.P. ,. (1999) Am. J. Hematol. ,:169.,Bihl, M.P. ,. (2002) Am. J. Respir. Cell Mol. Biol. ,:48.,Alberti, L. ,. (2005) Cancer Res. ,:2.,Murakami, M. ,. (1993) Science ,:1808.,Muller-Newen, G. (2003) Sci. STKE ,:PE40.,Mitsuyama, K. ,. (2006) Clin. Exp. Immunol. ,:125.,Cerutti, A. ,. (1998) J. Immunol. ,:2145.",,">95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.",,https://www.novusbio.com/products/recombinant-human-il-6-hek293-expressed-protein_7270-il
"B cell growth factor 1,BCDF,B-cell stimulatory factor 1,BCGF1,BCGF-1,binetrakin,BSF1,BSF-1,IL4,IL-4,IL-4B_cell stimulatory factor 1,interleukin 4,interleukin-4,Lymphocyte stimulatory factor 1,MGC79402,pitrakinra",,,"Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa ‑ 18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1 ‑ 3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four  alpha -helix structure (4). Human IL-4 is synthesized with a 24 aa signal sequence. Alternate splicing generates an isoform with a 16 aa internal deletion. Mature human IL-4 shares 55%, 39% and 43% aa sequence identity with bovine, mouse, and rat IL-4, respectively. Human, mouse, and rat IL-4 are species-specific in their activities (5 - 7). IL-4 exerts its effects through two receptor complexes (8, 9). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R alpha  and the common  gamma  chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and ‑21). The type II receptor on nonhematopoietic cells consists of IL-4 R alpha  and IL-13 R alpha 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4+ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgG4 and IgE in human B cells, acquisition of the Th2 phenotype by naïve CD4+ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (10 ‑ 13). IL-4 plays a dominant role in the development of allergic inflammation and asthma (12, 14).",,,,6507-IL-010,Recombinant Human IL-4 (CHO-expressed) Protein,"Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. ,:109.,Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. ,:1.,Yokota, T. , (1986) Proc. Natl. Acad. Sci. ,:5894.,Redfield, C. , (1991) Biochemistry ,:11029.,Ramirez, F. , (1988) J. Immunol. Meth. ,:141.,Leitenberg, D. and T.L. Feldbush (1988) Cell. Immunol. ,:451.,Mosman, T.R. , (1987) J. Immunol. ,:1813.,Mueller, T.D. , (2002) Biochim. Biophys. Acta ,:237.,Nelms, K. , (1999) Annu. Rev. Immunol. ,:701.,Paludan, S.R. (1998) Scand. J. Immunol. ,:459.,Corthay, A. (2006) Scand. J. Immunol. ,:93.,Ryan, J.J. , (2007) Crit. Rev. Immunol. ,:15.,Grone, A. (2002) Vet. Immunol. Immunopathol. ,:1.,Rosenberg, H.F. , (2007) J. Allergy Clin. Immunol. ,:1303.",,<0.01 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-il-4-cho-expressed-protein_6507-il
"colony stimulating factor 2 (granulocyte-macrophage),Colony-stimulating factor,CSF,CSF2,GMCSF,GM-CSF,GMCSFgranulocyte-macrophage colony-stimulating factor,granulocyte-macrophage colony stimulating factor,MGC131935,MGC138897,molgramostin,sargramostim",,,,,,,7954-GM-010,Recombinant Human GM-CSF (CHO-expressed) Protein,"Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. ,:653. ,Barreda, D.R. ,. (2004) Dev. Comp. Immunol. ,:509. ,Eksioglu, E.A. ,. (2007) Exp. Hematol. ,:1163. ,Cao, Y. (2007) J. Clin. Invest. ,:2362. ,Fleetwood, A.J. ,. (2005) Crit. Rev. Immunol. ,:405.,Heuser, M. ,. (2007) Semin. Hematol. ,:148. ,Hege, K.M. ,. (2006) Int. Rev. Immunol. ,:321. ,Kaushansky, K. ,. (1992) Biochemistry ,:1881. ,Diederichs, K. ,. (1991) Science ,:1779.  
,Cantrell, M.A. ,. (1985) Proc. Natl. Acad. Sci. ,:6250. 
,Lee, F. ,. (1985) Proc. Natl. Acad. Sci. ,:4360. 
,Wong, G.G. ,. (1985) Science ,:810. 
,Onetto-Pothier, N. ,. (1990) Blood ,:59. 
,Hayashida, K. ,. (1990) Proc. Natl. Acad. Sci. ,:9655. 
,Pelley, J.L. ,. (2007) Exp. Hematol. ,:1483. 
,Hogge, G.S. ,. (1990) Cancer Gene Ther. ,:26. 
,Sprague, W.S. ,. (2005) J. Comp. Pathol. ,:136. 
,Shanafelt, A.B. ,. (1991) J. Biol. Chem. ,:13804.",,<0.01 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-gm-csf-cho-expressed-protein_7954-gm
"catabolin,IL1 beta,IL-1 beta,IL-1,IL1B,IL-1b,IL1-BETA,IL-1F2,IL1F2IL-1 beta,interleukin 1, beta,interleukin-1 beta,preinterleukin 1 beta,pro-interleukin-1-beta",,,"IL-1 is a name that designates two pleiotropic cytokines, IL-1 alpha  (IL-1F1) and IL-1 beta  (IL-1F2), which are the products of distinct genes. IL-1 alpha  and IL-1 beta  are structurally related polypeptides that share approximately 21% amino acid (aa) identity in human. Both proteins are produced by a wide variety of cells in response to inflammatory agents, infections, or microbial endotoxins. While IL-1 alpha  and IL-1 beta  are regulated independently, they bind to the same receptor and exert identical biological effects. IL-1 RI binds directly to IL-1 alpha  or IL-1 beta  and then associates with IL-1 R accessory protein (IL-1 R3/IL-1 R AcP) to form a high-affinity receptor complex that is competent for signal transduction. IL-1 RII has high affinity for IL-1 beta  but functions as a decoy receptor and negative regulator of IL-1 beta  activity. IL-1ra functions as a competitive antagonist by preventing IL-1 alpha  and IL-1 beta  from interacting with IL-1 RI (1-4). The human IL-1 beta  cDNA encodes a 269 aa precursor. A 116 aa propeptide is cleaved intracellularly by the cysteine protease IL-1 beta -converting enzyme (Caspase-1/ICE) to generate the active cytokine (5-7). The 17 kDa mature human IL-1 beta  shares 96% aa sequence identity with rhesus and 67%-78% with canine, cotton rat, equine, feline, mouse, porcine, and rat IL-1 beta.",,,,201-LB-005,Recombinant Human IL-1 beta/IL-1F2 Protein,"Allan, S.M. ,. (2005) Nat. Rev. Immunol. ,:629.,Boraschi, D. and A. Tagliabue (2006) Vitam. Horm. ,:229.,Kornman, K.S. (2006) Am. J. Clin. Nutr. ,:475S.,Isoda, K. and F. Ohsuzu (2006) J. Atheroscler. Thromb. ,:21.,March, C.J. ,. (1985) Nature ,:641.,Auron, P.E. ,. (1984) Proc. Natl. Acad. Sci. ,:7907.,Martinon, F. and J. Tschopp (2007) Cell Death Differ. ,:10. ",,IL1B,,https://www.novusbio.com/products/recombinant-human-il-1-beta-il-1f2-protein_201-lb
"APC1 protein,Cachectin,Cachetin,DIF,TNF,TNF, monocyte-derived,tnfa,tnf-a,TNFalpha,TNF-alpha,TNF-alphacachectin,TNFATNF, macrophage-derived,TNFSF1A,TNFSF2,TNFSF2TNF superfamily, member 2,tumor necrosis factor (TNF superfamily, member 2),tumor necrosis factor alpha,Tumor necrosis factor ligand superfamily member 2,tumor necrosis factor,tumor necrosis factor-alpha",,,,,,,210-TA-005,Recombinant Human TNF-alpha Protein,"Zelova, H. and J. Hosek (2013) Inflamm. Res. ,:641.,Juhasz, K. ,. (2013) Expert Rev. Clin. Immunol. ,:335.,Pennica, D. ,. (1984) Nature ,:724.,Tang, P. ,. (1996) Biochemistry ,:8216.,Perez, C. ,. (1990) Cell ,:251.,Black, R.A. ,. (1997) Nature ,:729.,Moss, M.L. ,. (1997) Nature ,:733.,Gearing, A.J.H. ,. (1994) Nature ,:555.,Schall, T.J. ,. (1990) Cell ,:361.,Loetscher, H. ,. (1990) Cell ,:351.,Dembic, Z. ,. (1990) Cytokine ,:231.,Smith, C.A. ,. (1990) Science ,:1019.,Loetscher, H. ,. (1991) J. Biol. Chem. ,:18324.,Pinckard, J.K. ,. (1997) J. Biol. Chem. ,:10784.,Engelmann, H. ,. (1990) J. Biol. Chem. ,:1531.",,<0.10 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-tnf-alpha-protein_210-ta
"beta-urogastrone,EGF,epidermal growth factor (beta-urogastrone),epidermal growth factor,HOMG4,pro-epidermal growth factor,URG,Urogastrone",,,,,,,236-EG-200,"Recombinant Human EGF Protein, CF","Harris, R.C. ,. (2003) Exp. Cell Res. ,:2.,Carpenter, G. and Cohen, S. (1990) J. Biol. Chem. ,:7709.,Bell, G.I. ,. (1986) Nucl. Acids Res. ,:8427.,Carpenter, G. and Zendegui, J.G. (1986) Exp. Cell Res. ,:1.,Jorissen, R.N. ,. (2003) Exp. Cell Res. ,:31.,Gamett, D.C. ,. (1997) J. Biol. Chem. ,:12052.,Qian, X. ,. (1994) Proc. Natl. Acad. Sci. ,:1500.,Qian, X. ,. (1999) J. Biol. Chem. ,:574.",,EGF,,https://www.novusbio.com/products/recombinant-human-egf-protein-cf_236-eg
"IFG,IFI,IFNG,IFNgamma,IFN-gamma,Immune interferon,interferon gamma,interferon, gamma",,,,,,,285-IF-100,Recombinant Human IFN-gamma Protein,"Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. ,:97.,Pestka, S. ,. (2004) Immunol. Rev. ,:8.,Gray, P.W. and D.V. Goeddel (1982) Nature ,:859.,Marsters, S.A. ,. (1995) Proc. Natl. Acad. Sci. ,:5401.,Krause, C.D. ,. (2000) J. Biol. Chem. ,:22995.,Schroder, K. ,. (2004) J. Leukoc. Biol. ,:163.,McLaren, J.E. and D.P. Ramji (2009) Cytokine Growth Factor Rev. ,:125.,Muhl, H. and J. Pfeilschifter (2003) Int. Immunopharmacol. ,:1247.,Kelchtermans, H. ,. (2008) Trends Immunol. ,:479.",,<0.01 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-ifn-gamma-protein_285-if
"BMP-2B,BMP2B1,BMP2BMCOPS6,BMP4,BMP-4,Bone morphogenetic protein 2B,bone morphogenetic protein 4,DVR4,OFC11,ZYME",,,"BMP-4 is a TGF-beta  superfamily ligand that is widely expressed from early embryogenesis through adulthood. It plays an important role in mesenchyme formation, epidermal determination, suppression of neural induction, the development of multiple organs, and tissue repair (1-5). The human BMP-4 precursor contains a 273 amino acid (aa) propeptide and a 116 aa mature protein (6). Processing of the propeptide by furin or proprotein convertase 6 enables the formation of the mature disulfide-linked homodimeric BMP-4 and facilitates its secretion. Similar intracellular processes may lead to the formation and recreation of BMP4/BMP7,disulfide-linked heterodimer (7-9). Mature human and mouse BMP-4 share 98% aa sequence identity. Human BMP-4 shares 85% aa sequence identity with human BMP-2 and less than 50% with other human BMPs. Compared to BMP-4 homodimers, BMP-4/BMP-7 heterodimers exhibit a greater potency in inducing osteogenic differentiation (9). In Xenopus, the heterodimers can also induce the formation of mesoderm, whereas BMP-4 homodimers only provide ventralizing signals for existing mesoderm (10). BMP-4 signals through tetrameric complexes composed of type I (primarily Activin RIA or BMPR-IA) and type II (primarily Activin RIIA or BMPR-II) receptors (11, 12). The bioavailability of BMP-4 is regulated by its interaction with multiple proteins and glycosaminoglycans (13-15)., ",,,,314-BP-010,Recombinant Human BMP-4 Protein,"Zhang, P. ,. (2008) Blood ,:1933. ,Gambaro, K. ,. (2006) Cell Death Differ. ,:1075. ,Simic, P. and S. Vukicevic (2005) Cytokine Growth Factor Rev. ,:299. ,Sadlon, T.J. ,. (2004) Stem Cells ,:457. ,Frank, D.B. ,. (2005) Circ. Res. ,:496. ,Wozney, J. ,. (1988) Science ,:1528. ,Cui, Y. ,. (1998) EMBO J. ,:4735. ,Cui, Y. ,. (2001) Genes Dev. ,:2797. 
,Aono, A. ,. (1995) Biochem. Biophys. Res. Commun. ,:670. 
,Nishimatsu, S. and G.H. Thomsen (1998) Mech. Dev. ,:75. 
,Chen, D. ,. (2004) Growth Factors ,:233. 
,Lavery, K. ,. (2008) J. Biol. Chem. April 24 epub. 
,Rosen, V. (2006) Ann. N.Y. Acad. Sci. ,:19. 
,Jones, C.M. and J.C. Smith (1998) Dev. Biol. ,:12. 
,Takada, T. ,. (2003) J. Biol. Chem. ,:43229.",,<0.01 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-bmp-4-protein_314-bp
"basic fibroblast growth factor bFGF,Basic fibroblast growth factor,bFGF,FGF basic,FGF2,FGF-2,FGF2AS,FGFBprostatropin,fibroblast growth factor 2 (basic),GFG1,HBGF-2,HBGH-2,heparin-binding growth factor 2,NUDT6,Prostatropin",,,"FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. A variety of forms of FGF basic are produced as a result of N-terminal extensions. These extensions affect localization of FGF basic in cellular compartments but do not affect biological activity. Binding of FGF to heparin or cell surface heparan sulfate proteoglycans is necessary for binding of FGF to high affinity FGF receptors. FGF acidic and basic appear to bind to the same high affinity receptors and show a similar range of biological activities. FGF basic stimulates the proliferation of all cells of mesodermal origin and many cells of neuroectodermal, ectodermal, and endodermal origin. FGF basic induces neuron differentiation, survival, and regeneration. FGF basic also modulates embryonic development and differentiation. These observed ,functions of FGF basic suggest FGF basic may play a role ,in the modulation of such normal processes as angiogenesis, wound healing and tissue repair, embryonic development and differentiation, and neuronal function and neural degeneration. Additionally, FGF basic may participate in the production of a variety of pathological conditions resulting from excessive cell proliferation and excessive angiogenesis.",,,,233-FB-010,Recombinant Human FGF basic/FGF2 (146 aa) Protein,"Coulier, F. ,. (1997) J. Mol. Evol. ,:43.,Chen, C.H. ,. (2004) Curr. Vasc. Pharmacol. ,:33.,Mohammadi, M. ,. (2005) Curr. Opin. Struct. Biol. ,:506.,Fernig, D. ,. (1994) Prog. Growth Factor Res. ,:353.",,">97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.",,https://www.novusbio.com/products/recombinant-human-fgf-basic-fgf2-146-aa-protein_233-fb
"Activin A,activin AB alpha polypeptide,Activin beta-A chain,erythroid differentiation factor,Erythroid differentiation protein,follicle-stimulating hormone-releasing protein,FSH-releasing protein,inhibin beta A chain,inhibin beta A subunit,Inhibin, beta-1",,,,,,,338-AC-010,Recombinant Human/Mouse/Rat Activin A Protein,"Kumanov, P. ,. (2005) Reprod. Biomed. Online ,:786.,Maeshima, A. ,. (2008) Endocr. J. ,:1.,Rodgarkia-Dara, C. ,. (2006) Mutat. Res. ,:123.,Werner, S. and C. Alzheimer (2006) Cytokine Growth Factor Rev. ,:157.,Xu, P. and A.K. Hall (2006) Dev. Biol. ,:303.,Shav-Tal, Y. and D. Zipori (2002) Stem Cells ,:493.,Chen, Y.G. ,. (2006) Exp. Biol. Med. ,:534.,Gray, A.M. and A.J. Mason (1990) Science ,:1328.,Mason, A.J. ,. (1996) Mol. Endocrinol. ,:1055.,Thompson, T.B. ,. (2004) Mol. Cell. Endocrinol. ,:9.,Harrison, C.A. ,. (2005) Trends Endocrinol. Metab. ,:73.,Onichtchouk, D. ,. (1999) Nature ,:480.,Gray, P.C. ,. (2002) Mol. Cell. Endocrinol. ,:254.,Kelber, J.A. ,. (2008) J. Biol. Chem. ,:4490.,Phillips, D.J. ,. (1997) J. Endocrinol. ,:65.,Schneyer, A. ,. (2003) Endocrinology ,:1671.",,">95%, by SDS-PAGE with silver staining.",,https://www.novusbio.com/products/recombinant-human-mouse-rat-activin-a-protein_338-ac
"c-kit Ligand,DKFZp686F2250,familial progressive hyperpigmentation 2,FPH2,KIT ligand,Kitl,KITLG,KL-1,Mast cell growth factor,MGF,MGFSHEP7,SCF,SCFStem cell factor,SFc-Kit ligand,SLF,steel factor",,,,,,,7466-SC-010,Recombinant Human SCF (Mammalian-expressed) Protein,"Ashman, L.K., 1999, Int. J. Biochem. Cell Biol. ,:1037.,Sette, C. ,., 2000, Int. J. Dev. Biol. ,:599.,Yoshida, H. ,., 2001, J. Invest. Dermatol. Symp. Proc. ,:1.,Erlandsson, A. ,., 2004, Exp. Cell Res. ,:201.,Kapur, R. ,., 2002, Blood ,:1287.,Wang, C.-H. ,., 2007, Arterioscler. Thromb. Vasc. Biol. ,:540.,Bashamboo, A. ,., 2006, J. Cell Sci. ,:3039.,Reber, L. ,., 2006, Eur. J. Pharmacol. ,:327.,Martin, F.H. ,., 1990, Cell ,:203.,Arakawa, T. ,., 1991, J. Biol. Chem. ,:18942.,Majumdar, M.K. ,., 1994, J. Biol. Chem. ,:1237.,Brannan, C.I. ,., 1991, Proc. Natl. Acad. Sci. USA ,:4671.,13. Anderson, D.M. ,., 1991, Cell Growth Differ. ,:373.,14. Lemmon, M.A. ,., 1997, J. Biol. Chem. ,:6311.,15. Kanellakis, P. ,., 2006, Cardiovasc. Res. ,:117.",,<0.10 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-scf-mammalian-expressed-protein_7466-sc
"MVCD1,VAS,vascular endothelial growth factor A,Vascular permeability factor,Vasculotropin,VEGF,VEGFA,VEGF-A,VEGFMGC70609,VPF,VPFvascular endothelial growth factor",,,"Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF, appears to be the most abundant and potent isoform, followed by VEGF, and VEGF, (3, 4). Isoforms other than VEGF, contain basic heparin-binding regions and are not freely diffusible (4). Human VEGF, shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF, binds the semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2 (5). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (8). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha  (3, 4, 9). ",,,,293-VE-010,Recombinant Human VEGF 165 Protein,"Leung, D.W. , (1989) Science ,:1306. ,Keck, P.J. , (1989) Science ,:1309. ,Byrne, A.M. , (2005) J. Cell. Mol. Med. ,:777. ,Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. ,:853.,Pan, Q. , (2007) J. Biol. Chem. ,:24049.,Weis, S.M. and D.A. Cheresh (2005) Nature ,:497.,Thurston, G. (2002) J. Anat. ,:575.,Carvalho, J.F. , (2007) J. Clin. Immunol. ,:246.,Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. ,:2825.",,Ala27,,https://www.novusbio.com/products/recombinant-human-vegf-165-protein_293-ve
"aldesleukin,IL2,IL-2,IL-2lymphokine,interleukin 2,interleukin-2,involved in regulation of T-cell clonal expansion,T cell growth factor,T-cell growth factor,TCGF",,,"Interleukin-2 (IL-2) is a O-glycosylated, four  alpha -helix bundle cytokine that has potent stimulatory activity for antigen-activated T cells. It is expressed by CD4, and CD8, T cells,  gamma δ T cells, B cells, dendritic cells, and eosinophils (1-3). Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit cross-species activity (4). The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes (5-7). The 55 kDa IL-2 R alpha  is specific for IL-2 and binds with low affinity. The 75 kDa IL-2 R beta, which is also a component of the IL-15 receptor, binds IL-2 with intermediate affinity. The 64 kDa common gamma chain  gamma c/IL-2 R gamma, which is shared with the receptors for IL-4, -7, -9, -15, and -21, does not independently interact with IL-2. Upon ligand binding, signal transduction is performed by both IL-2 R beta  and  gamma c. IL-2 is best known for its autocrine and paracrine activity on T cells. It drives resting T cells to proliferate and induces IL-2 and IL-2 R alpha  synthesis (1, 2). It contributes to T cell homeostasis by promoting the Fas-induced death of naïve CD4, T cells but not activated CD4, memory lymphocytes (8). IL-2 plays a central role in the expansion and maintenance of regulatory T cells, although it inhibits the development of Th17 polarized cells (9-11). Thus, IL-2 may be a key cytokine in the natural suppression of autoimmunity (12, 13).",,,,202-IL-010,Recombinant Human IL-2 Protein,"Ma, A. ,. (2006) Annu. Rev. Immunol. ,:657. ,Gaffen, S.L. and K.D. Liu (2004) Cytokine ,:109. ,Taniguchi, T. ,. (1983) Nature ,:305. ,Mosmann, T.R. ,. (1987) J. Immunol. ,:1813. ,Liparoto, S.F. ,. (2002) Biochemistry ,:2543. ,Wang, X. ,. (2005) Science ,:1159. ,Bodnar, A. ,. (2008) Immunol. Lett. ,:117. ,Jaleco, S. ,. (2003) J. Immunol. ,:61.,Malek, T.R. (2003) J. Leukoc. Biol. ,:961.,Laurence, A. ,. (2007) Immunity ,:371.,Kryczek, I. ,. (2007) J. Immunol. ,:6730.,Afzali, B. ,. (2007) Clin. Exp. Immunol. ,:32.,Fehervari, Z. ,. (2006) Trends Immunol. ,:109.",,<0.10 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-human-il-2-protein_202-il
"colony stimulating factor 1 (macrophage),CSF1,CSF-1,Lanimostim,macrophage colony stimulating factor,macrophage colony-stimulating factor 1,MCSF,M-CSF,MCSFlanimostim,MGC31930",,,"M-CSF, also known as CSF-1, is a four-alpha -helical-bundle cytokine that is the primary regulator of macrophage survival, proliferation and differentiation (1-3). M-CSF is also essential for the survival and proliferation of osteoclast progenitors (1, 4). M-CSF also primes and enhances macrophage killing of tumor cells and microorganisms, regulates the release of cytokines and other inflammatory modulators from macrophages, and stimulates pinocytosis (2, 3). M-CSF increases during pregnancy to support implantation and growth of the decidua and placenta (5). Sources of M-CSF include fibroblasts, activated macrophages, endometrial secretory epithelium, bone marrow stromal cells and activated endothelial cells (1-5). The M-CSF receptor (,) transduces its pleotropic effects and mediates its endocytosis. M-CSF mRNAs of various sizes occur (3-9). Full length mouse M-CSF transcripts encode a 520 amino acid (aa) type I transmembrane (TM) protein with a 462 aa extracellular region, a 21 aa TM domain, and a 37 aa cytoplasmic tail that forms a 140 kDa covalent dimer. Differential processing produces two proteolytically cleaved, secreted dimers. One is an N- and O- glycosylated 86 kDa dimer, while the other is modified by both glycosylation and chondroitin-sulfate proteoglycan (PG) to generate a 200 kDa subunit. Although PG-modified M-CSF can circulate, it may be immobilized by attachment to type V collagen (8). Shorter transcripts encode M‑CSF that lacks cleavage and PG sites and produces an N-glycosylated 68 kDa TM dimer and a slowly produced 44 kDa secreted dimer (7). Although forms may vary in activity and half-life, all contain the N-terminal 150 aa portion that is necessary and sufficient for interaction with the M-CSF receptor (10, 11). The first 229 aa of mature mouse M-CSF shares 87%, 83%, 82% and 81% aa identity with corresponding regions of rat, dog, cow and human M-CSF, respectively (12, 13). Human M‑CSF is active in the mouse, but mouse M-CSF is reported to be species-specific.",,,,416-ML-010,Recombinant Mouse M-CSF Protein,"Pixley, F.J. and E.R. Stanley (2004) Trends Cell Biol. ,:628.,Chitu, V. and E.R. Stanley (2006) Curr. Opin. Immunol. ,:39.,Fixe, P. and V. Praloran (1997) Eur. Cytokine Netw. ,:125.,Ryan, G.R. , (2001) Blood ,:74.,Makrigiannakis, A. , (2006) Trends Endocrinol. Metab. ,:178.,Nandi, S. , (2006) Blood ,:786.,Rettenmier, C.W. and M.F. Roussel (1988) Mol. Cell Biol. ,:5026.,Suzu, S. , (1992) J. Biol. Chem. ,:16812.,Manos, M.M. (1988) Mol. Cell. Biol. ,:5035.,Koths, K. (1997) Mol. Reprod. Dev. ,:31.,Jang, M-H. , (2006) J. Immunol. ,:4055.,DeLamarter, J.F. , (1987) Nucleic Acids Res. ,:2389.,Ladner, M.B. , (1988) Proc. Natl. Acad. Sci. USA ,:6706. ",,<1.0 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-mouse-m-csf-protein_416-ml
"B cell growth factor 1,BCDF,B-cell stimulatory factor 1,BCGF1,BCGF-1,binetrakin,BSF1,BSF-1,IL4,IL-4,IL-4B_cell stimulatory factor 1,interleukin 4,interleukin-4,Lymphocyte stimulatory factor 1,MGC79402,pitrakinra",,,"Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa‑18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1‑3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four  alpha -helix structure (4). Human IL-4 is synthesized with a 24 aa signal sequence. Alternate splicing generates an isoform with a 16 aa internal deletion. Mature human IL-4 shares 55%, 39% and 43% aa sequence identity with bovine, mouse, and rat IL-4, respectively. Human, mouse, and rat IL-4 are species-specific in their activities (5‑7). IL-4 exerts its effects through two receptor complexes (8, 9). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R alpha  and the common  gamma  chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and ‑21). The type II receptor on nonhematopoietic cells consists of IL-4 R alpha  and IL‑13 R alpha 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4, T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgG4 and IgE in human B cells, acquisition of the Th2 phenotype by naïve CD4, T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (10‑13). IL-4 plays a dominant role in the development of allergic inflammation and asthma (12, 14).",,,,204-IL-010,Recombinant Human IL-4 Protein,"Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. ,:109.,Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. ,:1.,Yokota, T. ,. (1986) Proc. Natl. Acad. Sci. ,:5894.,Redfield, C. ,. (1991) Biochemistry ,:11029.,Ramirez, F. ,. (1988) J. Immunol. Meth. ,:141.,Leitenberg, D. and T.L. Feldbush (1988) Cell. Immunol. ,:451.,Mosman, T.R. ,. (1987) J. Immunol. ,:1813.,Mueller, T.D. ,. (2002) Biochim. Biophys. Acta ,:237.,Nelms, K. ,. (1999) Annu. Rev. Immunol. ,:701.,Paludan, S.R. (1998) Scand. J. Immunol. ,:459.,Corthay, A. (2006) Scand. J. Immunol. ,:93.,Ryan, J.J. ,. (2007) Crit. Rev. Immunol. ,:15.,Grone, A. (2002) Vet. Immunol. Immunopathol. ,:1.,Rosenberg, H.F. ,. (2007) J. Allergy Clin. Immunol. ,:1303.",,">97%, by SDS-PAGE under reducing conditions and visualized by silver stain.",,https://www.novusbio.com/products/recombinant-human-il-4-protein_204-il
"B cell growth factor 1,BCDF,B-cell stimulatory factor 1,BCGF1,BCGF-1,binetrakin,BSF1,BSF-1,IL4,IL-4,IL-4B_cell stimulatory factor 1,interleukin 4,interleukin-4,Lymphocyte stimulatory factor 1,MGC79402,pitrakinra",,,"Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa-18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1-4). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four  alpha -helix structure (5). Mouse IL-4 is synthesized with a 24 aa signal sequence. Mature mouse IL-4 shares 39%, 39%, and 59% aa sequence identity with bovine, human, and rat IL-4, respectively. Human, mouse, and rat IL-4 are species-specific in their activities (6-8). IL-4 exerts its effects through two receptor complexes (9, 10). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R alpha  and the common  gamma  chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and,-21). The type II receptor on nonhematopoietic cells consists of IL‑4 R alpha  and IL‑13 R alpha 1. The type II receptor also transduces IL‑13 mediated signals. IL-4 is primarily expressed by Th2‑biased CD4, T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgG1 and IgE in mouse B cells, acquisition of the Th2 phenotype by naïve CD4, T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (11 ‑ 14). IL-4 plays a dominant role in the development of allergic inflammation and asthma (13, 15).",,,,404-ML-010,Recombinant Mouse IL-4 Protein,"Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. ,:109.,Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. ,:1.,Lee, F. ,. (1986) Proc. Natl. Acad. Sci. ,:2061.,Noma, Y. ,. (1986) Nature ,:640.,Redfield, C. ,. (1991) Biochemistry ,:11029.,Ramirez, F. ,. (1988) J. Immunol. Meth. ,:141.,Leitenberg, D. and T.L. Feldbush (1988) Cell. Immunol. ,:451.,Mosman, T.R. ,. (1987) J. Immunol. ,:1813.,Mueller, T.D. ,. (2002) Biochim. Biophys. Acta ,:237.,Nelms, K. ,. (1999) Annu. Rev. Immunol. ,:701.,Paludan, S.R. (1998) Scand. J. Immunol. ,:459.,Corthay, A. (2006) Scand. J. Immunol. ,:93.,Ryan, J.J. ,. (2007) Crit. Rev. Immunol. ,:15.,Grone, A. (2002) Vet. Immunol. Immunopathol. ,:1.,Rosenberg, H.F. ,. (2007) J. Allergy Clin. Immunol. ,:1303.",,14 kDa.,,https://www.novusbio.com/products/recombinant-mouse-il-4-protein_404-ml
"B cell stimulatory factor-2,B-cell differentiation factor,BSF-2,BSF2CTL differentiation factor,CDF,HGFHSFIFNB2Hybridoma growth factor,IFN-beta-2,IL6,IL-6,IL-6B-cell stimulatory factor 2,Interferon beta-2,interleukin 6 (interferon, beta 2),interleukin BSF-2,interleukin-6,MGI-2A",,,,,,,206-IL-010,Recombinant Human IL-6 Protein,"Mansell, A. and B.J. Jenkins (2013) Cytokine Growth Factor Rev. ,:249.,Schuett, H. , (2009) Thromb. Haemost. ,:215.,Erta, M. ,. (2012) Int. J. Biol. Sci. ,:1254.,Garbers, C. ,. (2012) Cytokine Growth Factor Rev. ,:85.,Mihara, M. ,. (2012) Clin. Sci. (Lond.) ,:143.,Hirano, T. ,. (1986) Nature ,:73.,Kestler, D.P. ,. (1995) Blood ,:4559.,Kestler, D.P. ,. (1999) Am. J. Hematol. ,:169.,Bihl, M.P. ,. (2002) Am. J. Respir. Cell Mol. Biol. ,:48.,Alberti, L. ,. (2005) Cancer Res. ,:2.,Murakami, M. ,. (1993) Science ,:1808.,Muller-Newen, G. (2003) Sci. STKE ,:PE40.,Mitsuyama, K. ,. (2006) Clin. Exp. Immunol. ,:125.,Cerutti, A. , (1998) J. Immunol. ,:2145.",,Recombinant Proteins,,https://www.novusbio.com/products/recombinant-human-il-6-protein_206-il
"IFG,IFI,IFNG,IFNgamma,IFN-gamma,Immune interferon,interferon gamma,interferon, gamma",,,,,,,485-MI-100,Recombinant Mouse IFN-gamma Protein,"Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. ,:97.,Pestka, S. ,. (2004) Immunol. Rev. ,:8.,Gray, P.W. and D.V. Goeddel (1983) Proc. Natl. Acad. Sci. ,:5842.,Marsters, S.A. ,. (1995) Proc. Natl. Acad. Sci. ,:5401.,Krause, C.D. ,. (2000) J. Biol. Chem. ,:22995.,Schroder, K. ,. (2004) J. Leukoc. Biol. ,:163.,McLaren, J.E. and D.P. Ramji (2009) Cytokine Growth Factor Rev. ,:125.,Muhl, H. and J. Pfeilschifter (2003) Int. Immunopharmacol. ,:1247.,Kelchtermans, H. ,. (2008) Trends Immunol. ,:479.",,<0.10 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-mouse-ifn-gamma-protein_485-mi
"colony stimulating factor 2 (granulocyte-macrophage),Colony-stimulating factor,CSF,CSF2,GMCSF,GM-CSF,GMCSFgranulocyte-macrophage colony-stimulating factor,granulocyte-macrophage colony stimulating factor,MGC131935,MGC138897,molgramostin,sargramostim",,,,,,,215-GM-010,Recombinant Human GM-CSF Protein,"Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. ,:653. ,Barreda, D.R. ,. (2004) Dev. Comp. Immunol. ,:509. ,Eksioglu, E.A. ,. (2007) Exp. Hematol. ,:1163. ,Cao, Y. (2007) J. Clin. Invest. ,:2362. ,Fleetwood, A.J. ,. (2005) Crit. Rev. Immunol. ,:405.,Heuser, M. ,. (2007) Semin. Hematol. ,:148. ,Hege, K.M. ,. (2006) Int. Rev. Immunol. ,:321. ,Kaushansky, K. ,. (1992) Biochemistry ,:1881. ,Diederichs, K. ,. (1991) Science ,:1779.  
,Cantrell, M.A. ,. (1985) Proc. Natl. Acad. Sci. ,:6250. 
,Lee, F. ,. (1985) Proc. Natl. Acad. Sci. ,:4360. 
,Wong, G.G. ,. (1985) Science ,:810. 
,Onetto-Pothier, N. ,. (1990) Blood ,:59. 
,Hayashida, K. ,. (1990) Proc. Natl. Acad. Sci. ,:9655. 
,Pelley, J.L. ,. (2007) Exp. Hematol. ,:1483. 
,Hogge, G.S. ,. (1990) Cancer Gene Ther. ,:26. 
,Sprague, W.S. ,. (2005) J. Comp. Pathol. ,:136. 
,Shanafelt, A.B. ,. (1991) J. Biol. Chem. ,:13804.",,Recombinant Proteins,,https://www.novusbio.com/products/recombinant-human-gm-csf-protein_215-gm
"B cell stimulatory factor-2,B-cell differentiation factor,BSF-2,BSF2CTL differentiation factor,CDF,HGFHSFIFNB2Hybridoma growth factor,IFN-beta-2,IL6,IL-6,IL-6B-cell stimulatory factor 2,Interferon beta-2,interleukin 6 (interferon, beta 2),interleukin BSF-2,interleukin-6,MGI-2A",,,,,,,406-ML-005,Recombinant Mouse IL-6 Protein,"Mansell, A. and B.J. Jenkins (2013) Cytokine Growth Factor Rev. ,:249.,Schuett, H. , (2009) Thromb. Haemost. ,:215.,Erta, M. ,. (2012) Int. J. Biol. Sci. ,:1254.,Garbers, C. ,. (2012) Cytokine Growth Factor Rev. ,:85.,Mihara, M. ,. (2012) Clin. Sci. (Lond.) ,:143.,Chiu, C.P. ,. (1988) Proc. Natl. Acad. Sci. USA ,:7099.,Simpson, R.J. ,. (1988) Eur. J. Biochem. ,:187.,Van Snick, J. ,. (1988) Eur. J. Immunol. ,:193.,Murakami, M. ,. (1993) Science ,:1808.,Muller-Newen, G. (2003) Sci. STKE ,:PE40.,Mitsuyama, K. ,. (2006) Clin. Exp. Immunol. ,:125.,Cerutti, A. et al. (1998) J. Immunol. ,:2145.",,">97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.",,https://www.novusbio.com/products/recombinant-mouse-il-6-protein_406-ml
"colony stimulating factor 2 (granulocyte-macrophage),Colony-stimulating factor,CSF,CSF2,GMCSF,GM-CSF,GMCSFgranulocyte-macrophage colony-stimulating factor,granulocyte-macrophage colony stimulating factor,MGC131935,MGC138897,molgramostin,sargramostim",,,"GM-CSF was initially characterized as a factor that can support the ,colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3-5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled  alpha ‑helices (8-10). Mature mouse GM-CSF shares 49%-54% amino acid sequence identity with canine, feline, human, and porcine GM-CSF and 69% with rat GM‑CSF. GM‑CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common  beta  chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (11, 12). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha  (13). The activity of GM-CSF is species specific between human and mouse. Mouse GM-CSF is only weakly active on rat cells, although rat GM‑CSF is fully active on mouse cells (14, 15).",,,,415-ML-005,Recombinant Mouse GM-CSF Protein,"Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. ,:653. ,Barreda, D.R. ,. (2004) Dev. Comp. Immunol. ,:509. ,Eksioglu, E.A. ,. (2007) Exp. Hematol. ,:1163. ,Cao, Y. (2007) J. Clin. Invest. ,:2362. ,Fleetwood, A.J. ,. (2005) Crit. Rev. Immunol. ,:405. ,Heuser, M. ,. (2007) Semin. Hematol. ,:148. ,Hege, K.M. ,. (2006) Int. Rev. Immunol. ,:321. ,Kaushansky, K. ,. (1992) Biochemistry ,:1881. 
,Diederichs, K. ,. (1991) Science ,:1779. 
,Gough, N.M. ,. (1984) Nature ,:763. 
,Onetto-Pothier, N. ,. (1990) Blood ,:59. 
,Hayashida, K. ,. (1990) Proc. Natl. Acad. Sci. ,:9655. 
,Pelley, J.L. ,. (2007) Exp. Hematol. ,:1483. 
,Oaks, M.K. ,. (1995) J. Interferon Cytokine Res. ,:1095. 
,Vandenabeele, P. ,. (1990) Lymphokine Res. ,:381. ",,">97%, by SDS-PAGE under reducing conditions and visualized by silver stain.",,https://www.novusbio.com/products/recombinant-mouse-gm-csf-protein_415-ml
"APC1 protein,Cachectin,Cachetin,DIF,TNF,TNF, monocyte-derived,tnfa,tnf-a,TNFalpha,TNF-alpha,TNF-alphacachectin,TNFATNF, macrophage-derived,TNFSF1A,TNFSF2,TNFSF2TNF superfamily, member 2,tumor necrosis factor (TNF superfamily, member 2),tumor necrosis factor alpha,Tumor necrosis factor ligand superfamily member 2,tumor necrosis factor,tumor necrosis factor-alpha",,,,,,,410-MT-010,Recombinant Mouse TNF-alpha (aa 80-235) Protein,"Zelova, H. and J. Hosek (2013) Inflamm. Res. ,:641.,Juhasz, K. ,. (2013) Expert Rev. Clin. Immunol. ,:335.,Fransen, L. ,. (1985) Nucleic Acids Res. ,:4417.,Tang, P. ,. (1996) Biochemistry ,:8216.,Perez, C. ,. (1990) Cell ,:251.,Black, R.A. ,. (1997) Nature ,:729.,Moss, M.L. ,. (1997) Nature ,:733.,Gearing, A.J.H. ,. (1994) Nature ,:555.,Schall, T.J. ,. (1990) Cell ,:361.,Loetscher, H. ,. (1990) Cell ,:351.,Dembic, Z. ,. (1990) Cytokine ,:231.,Smith, C.A. ,. (1990) Science ,:1019.,Loetscher, H. ,. (1991) J. Biol. Chem. ,:18324.,Pinckard, J.K. ,. (1997) J. Biol. Chem. ,:10784.,Engelmann, H. ,. (1990) J. Biol. Chem. ,:1531.",,<0.01 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-mouse-tnf-alpha-aa-80-235-protein_410-mt
"ACHM7,Activating transcription factor 6 alpha,activating transcription factor 6,atf6 a,ATF6 alpha,ATF6,ATF6A,ATF6-alpha,cAMP-dependent transcription factor ATF-6 alpha,cyclic AMP-dependent transcription factor ATF-6 alpha",Mouse,Mouse,,Mouse,Mouse,Mouse,NBP1-40256SS,ATF6 Antibody (70B1413.1),,,,Mouse,https://www.novusbio.com/products/atf6-antibody-70b14131_nbp1-40256
"MGC119418,MGC119419,MGC119420,protein Wnt-3a,wingless-type MMTV integration site family, member 3A,Wnt3a,Wnt-3a",,,"Wnt-3a is one of 19 vertebrate members of the Wingless-type MMTV integration site (Wnt) family of highly conserved cysteine-rich secreted glycoproteins important for normal developmental processes (1). Wnts bind to the cell surface Frizzled family receptors in conjunction with low-density lipoprotein receptor-related protein family receptors (LRP5 or 6) resulting in the stabilization of intracellular  beta -catenin levels (2). As intracellular  beta -catenin levels rise,  beta -catenin binds to TCF/LEF transcription factors leading to expression of Wnt target genes (3). Endo-IWR 1 (Catalog # 3532, # PSM1324) is a cell-permeant small molecule inhibitor of Axin turnover that suppresses Wnt signal transduction by stabilizing the  beta -catenin destruction complex (4). Wnt-3a is a 44 kDa secreted hydrophobic glycoprotein containing a conserved pattern of 24 cysteine residues (5). Wnt-3a has two N-linked glycosylation sites (Asn 87, Asn 298), and Ser 209 is modified with palmitoleic acid (6). Glycosylation and acylation are essential for efficient Wnt secretion and biological activity, respectively (6, 7). Human Wnt-3a shares 96% amino acid (aa) identity with mouse mouse, bovine and canine Wnt-3a, and 89%, 86% and 84% aa identity with chicken, Xenopus and zebrafish Wnt-3a, respectively. It also shares 87% aa identity with Wnt3. During embryonic development, Wnt-3a is necessary for proper development of the hippocampus, anterior-posterior patterning, somite development, and tailbud formation (9-12). Wnt-3a also promotes self-renewal of hematopoietic stem cells, neural stem cells, and embryonic stem cells (13, 14).",,,,5036-WN-010,Recombinant Human Wnt-3a Protein,"Willert, K. and Nusse, R. (2012) Cold Spring Harb. Perspect. Biol. ,:a007864.,MacDonald, B.T. and X. He (2012) Cold Spring Harb. Perspect. Biol. ,:a007880.,Korinek, V. ,. (1997) Science ,:1784.,Chen, B. ,. (2009) Nat. Chem. Biol.,:100.,Smolich, B.D. ,. (1993) Mol. Biol. Cell ,:1267.,Takada, R. , (2006) Dev. Cell ,:791.,Komekado, H. (2007) Genes Cells ,:521.,Dunty Jr. W. C. ,(2008) Development ,:85.,Ikeya, M. and S. Takada (2001) Mech. Dev. ,:27.,Lee, S. M. ,(2000) Development ,:457.,Takada, S. ,(1994) Genes Dev. ,:174.,Willert, K. ,. (2003) Nature ,:6938.,Kalani, M.Y. ,. (2008) Proc. Natl. Acad. Sci. USA ,:16970.,Ten Berge, D. ,. (2011) Nat. Cell Biol. ,:1070.",,37.4 kDa.,,https://www.novusbio.com/products/recombinant-human-wnt-3a-protein_5036-wn
"ATV,AT-V1,AT-V2,Cell cycle regulatory protein p95,FLJ10155,MGC87362,NBN,Nbs1,NBS1P95,NBSNijmegen breakage syndrome protein 1,Nibrin,Nijmegen breakage syndrome 1 (nibrin),p95 protein of the MRE11/RAD50 complex,p95",95 kDa.,95 kDa.,,95 kDa.,95 kDa.,95 kDa.,NB100-143SS,Nbs1 Antibody,,,,,https://www.novusbio.com/products/nbs1-antibody_nb100-143
IgG1,,IGHG1,"R&D Systems offers a range of secondary antibodies and controls for flow cytometry, immunohistochemistry, and Western blotting. We provide species-specific secondary antibodies that are available with a variety of conjugated labels.,
Our NorthernLights fluorescent secondary antibodies are bright and resistant to photobleaching. We are currently offering secondary antibodies recognizing mouse, rat, goat, sheep, and rabbit IgG as well as chicken IgY. These reagents are available with three distinct excitation and emission maxima, making them ideal for multi-color fluorescence microscopy. ",,IGHG1,IGHG1,MAB002,Mouse IgG1 Isotype Control (11711) [Unconjugated],,,IGHG1,IGHG1,https://www.novusbio.com/products/igg1-isotype-control-11711_mab002
"CEDLAP,DPD1,latency-associated peptide,TGFB,TGFB1,TGF-beta 1 protein,TGFbeta 1,TGF-beta 1,TGFbeta,TGF-beta-1,transforming growth factor beta-1,transforming growth factor, beta 1",,,"TGF-beta 1 (transforming growth factor beta 1) is one of three closely related mammalian members of the large TGF‑ beta  superfamily that share a characteristic cystine knot structure (1‑7). TGF‑ beta 1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial‑mesenchymal transition (1‑4). Each TGF‑ beta  isoform has some non‑redundant functions; for TGF‑ beta 1, mice with targeted deletion show defects in hematopoiesis and endothelial differentiation, and die of overwhelming inflammation (2). Human or mouse TGF‑ beta 1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein (8). A furin‑like convertase processes the proprotein to generate an N‑terminal 249 aa latency‑associated peptide (LAP) and a C‑terminal 112 aa mature TGF‑ beta 1 (8, 9). Disulfide‑linked homodimers of LAP and TGF‑ beta 1 remain non‑covalently associated after secretion, forming the small latent TGF‑ beta 1 complex (8‑10). Covalent linkage of LAP to one of three latent TGF‑ beta  binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF‑ beta  is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature mouse TGF‑ beta 1 shares 99‑100% aa sequence identity with human, rat, equine, porcine, canine and bovine TGF‑ beta 1. It demonstrates cross‑species activity (1). TGF‑ beta 1 signaling begins with high‑affinity binding to a type II ser/thr kinase receptor termed TGF‑ beta  RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF‑ beta  RI (also called activin receptor‑like kinase (ALK) ‑5), or alternatively, ALK‑1. This complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Contributions of the accessory receptors betaglycan (also known as TGF‑ beta  RIII) and endoglin, or use of Smad‑independent signaling pathways, allow for disparate actions observed in response to TGF‑ beta  in different contexts (11).",,,,7666-MB-005,Recombinant Mouse TGF-beta 1 Protein,"Derynck, R. and K. Miyazono (2008) Cold Spring Harbor Laboratory Press, 29. ,Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. ,:6982. ,Wahl, S.M. (2006) Immunol. Rev. ,:213. ,Chang, H. , (2002) Endocr. Rev. ,:787. ,Lin, J.S. , (2006) Reproduction ,:179. ,Hinck, A.P. , (1996) Biochemistry ,:8517. ,Mittl, P.R.E. , (1996) Protein Sci. ,:1261. ,Derynck, R. ,. (1985) Nature ,:701. ,Miyazono, K. , (1988) J. Biol. Chem. ,:6407. ,Oklu, R. and R. Hesketh (2000) Biochem. J. ,:601. ,de Caestecker, M. , (2004) Cytokine Growth Factor Rev. ,:1. ,Zuniga, J.E. , (2005) J. Mol. Biol. ,:1052.",,<0.01 EU per 1 μg of the protein by the LAL method.,,https://www.novusbio.com/products/recombinant-mouse-tgf-beta-1-protein_7666-mb
"CLMF p35,CLMF1,Cytotoxic lymphocyte maturation factor 35 kDa subunit,IL-12 subunit p35,IL12,IL-12,IL-12, subunit p35,IL12A,interleukin 12, p35,interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocytematuration factor 1, p35),interleukin-12 alpha chain,interleukin-12 subunit alpha,natural killer cell stimulatory factor 1, 35 kD subunit,NF cell stimulatory factor chain 1,NK cell stimulatory factor chain 1,NKSF1,p35",,,"Interleukin 12, also known as Natural Killer Cell Stimulatory Factor (NKSF) or Cytotoxic Lymphocyte Maturation Factor (CLMF), is a heterodimeric pleiotropic cytokine made up of a 40 kDa (p40) subunit and a 35 kDa (p35) subunit. IL‑12 is produced by macrophages and B lymphocytes and has been shown to have multiple effects on T cells and Natural Killer (NK) cells. Some of these IL‑12 activities include the induction of IFN‑ gamma  and TNF in resting and activated T and NK cells; the enhancement of cytotoxic activity of resting NK and T cells, the stimulation of resting T cell proliferation in the presence of a comitogen; and the enhancement of NK cell proliferation. Current evidence indicates that IL‑12 is a key mediator of cellular-immunity and induces the differentiation of Th1 cells from precursor T helper cells. Based on its activities, it has been suggested that IL‑12 may have therapeutic potential as a vaccine adjuvant that promotes cellular-immunity and as an anti-tumor and anti-viral agent.,Human and mouse IL‑12 share 70% and 60% amino acid sequence identity in their p40 and p35 subunits, respectively. While mouse IL‑12 is active on both human and mouse cells, human IL‑12 is not active on murine cells. R&D Systems' recombinant mouse IL‑12 preparations were proteolytically cleaved between residues G158 and E159 of the mature p35 subunit. Thus, under reducing conditions, three bands representing the p40 subunit, the p35 R1 ‑ G158 peptide and the p35 E159 - A193 peptide can be observed in SDS-PAGE. The biological activity of this cleaved mouse IL‑12 is comparable to that of the intact human IL‑12.",,,,419-ML-010,Recombinant Mouse IL-12 Protein,,,">97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.",,https://www.novusbio.com/products/recombinant-mouse-il-12-protein_419-ml
"EC 2.7.11,ERK1,ERK-1,ERK1p44-MAPK,ERT2,Extracellular signal-regulated kinase 1,extracellular signal-related kinase 1,HS44KDAP,HUMKER1A,Insulin-stimulated MAP2 kinase,MAP kinase 1,MAP kinase 3,MAP kinase isoform p44,MAPK 1,MAPK 3,MAPK3,MGC20180,Microtubule-associated protein 2 kinase,Mitogen-activated protein kinase 1,mitogen-activated protein kinase 3,P44ERK1,p44-ERK1,p44mapk,PRKM3,PRKM3EC 2.7.11.24",," Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.",," Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors."," Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors."," Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.",NBP2-22203-0.025ml,ERK1 Antibody (1E5),,,,,https://www.novusbio.com/products/erk1-antibody-1e5_nbp2-22203
"colony stimulating factor 1 (macrophage),CSF1,CSF-1,Lanimostim,macrophage colony stimulating factor,macrophage colony-stimulating factor 1,MCSF,M-CSF,MCSFlanimostim,MGC31930",,,,,,,216-MC-005,Recombinant Human M-CSF Protein,"Pixley, F.J. and E.R. Stanley (2004) Trends Cell Biol. ,:628.,Chitu, V. and E.R. Stanley (2006) Curr. Opin. Immunol. ,:39.,Fixe, P. and V. Praloran (1997) Eur. Cytokine Netw. ,:125.,Ryan, G.R. , (2001) Blood ,:74.,Makrigiannakis, A. , (2006) Trends Endocrinol. Metab. ,:178.,Nandi, S. , (2006) Blood ,:786.,Rettenmier, C.W. and M.F. Roussel (1988) Mol. Cell Biol. ,:5026.,Suzu, S. , (1992) J. Biol. Chem. ,:16812.,Manos, M.M. (1988) Mol. Cell. Biol. ,:5035.,Koths, K. (1997) Mol. Reprod. Dev. ,:31.,Jang, M-H. , (2006) J. Immunol. ,:4055.,Kawasaki, E.S. ,. (1985) Science ,: 291.,Wong, G.G. ,. (1987) Science ,:1504.",,Recombinant Proteins,,https://www.novusbio.com/products/recombinant-human-m-csf-protein_216-mc
"catabolin,IL1 beta,IL-1 beta,IL-1,IL1B,IL-1b,IL1-BETA,IL-1F2,IL1F2IL-1 beta,interleukin 1, beta,interleukin-1 beta,preinterleukin 1 beta,pro-interleukin-1-beta",,,"IL-1 is a name that designates two pleiotropic cytokines, IL-1 alpha  (IL-1F1) and IL-1 beta  (IL-1F2), which are the products of distinct genes. IL-1 alpha  and IL-1 beta  are structurally related polypeptides that share approximately 17% amino acid (aa) identity in mouse. Both proteins are produced by a wide variety of cells in response to inflammatory agents, infections, or microbial endotoxins. While IL-1 alpha  and IL-1 beta  are regulated independently, they bind to the same receptor and exert identical biological effects. IL-1 RI binds directly to IL-1 alpha  or IL-1 beta  and then associates with IL-1 R accessory protein (IL-1 R3/IL-1 R AcP) to form a high-affinity receptor complex that is competent for signal transduction. IL-1 RII has high affinity for IL-1 beta  but functions as a decoy receptor and negative regulator of IL-1 beta  activity. IL-1ra functions as a competitive antagonist by preventing IL-1 alpha  and IL-1 beta  from interacting with IL-1 RI (1-4). The mouse IL-1 beta  cDNA encodes a 269 aa precursor. A 117 aa propeptide is cleaved intracellularly by the cysteine protease IL-1 beta -converting enzyme (Caspase-1/ICE) to generate the active cytokine (5, 6). The 17 kDa mature mouse IL-1 beta  shares 90% aa sequence identity with cotton rat and rat and 65%-78% identity with canine, equine, feline, human, porcine, and rhesus IL-1 beta.",,,,401-ML-005,Recombinant Mouse IL-1 beta/IL-1F2 Protein,"Allan, S.M. ,. (2005) Nat. Rev. Immunol. ,:629.,Boraschi, D. and A. Tagliabue (2006) Vitam. Horm. ,:229.,Kornman, K.S. (2006) Am. J. Clin. Nutr. ,:475S.,Isoda, K. and F. Ohsuzu (2006) J. Atheroscler. Thromb. ,:21.,Gray, P.W. ,. (1986) J. Immunol. ,:3644.,Martinon, F. and J. Tschopp (2007) Cell Death Differ. ,:10.
",,">97%, by SDS-PAGE under reducing conditions and visualized by silver stain.",,https://www.novusbio.com/products/recombinant-mouse-il-1-beta-il-1f2-protein_401-ml
